Stephanie CPA - GlycoMimetics Vice Accounting
| GLYC Stock | USD 0.32 0.01 3.03% |
Executive
Stephanie CPA is Vice Accounting of GlycoMimetics
| Age | 53 |
| Address | 9708 Medical Center Drive, Rockville, MD, United States, 20850 |
| Phone | 240 243 1201 |
| Web | https://www.glycomimetics.com |
GlycoMimetics Management Efficiency
The company has return on total asset (ROA) of (0.5925) % which means that it has lost $0.5925 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0449) %, meaning that it created substantial loss on money invested by shareholders. GlycoMimetics' management efficiency ratios could be used to measure how well GlycoMimetics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.85. In addition to that, Return On Capital Employed is expected to decline to -1.07. At present, GlycoMimetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.1 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Cathy Chang | Bioatla | N/A | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Lucinda Warren | Cue Biopharma | N/A | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| Michael JD | Foghorn Therapeutics | 59 | |
| Jonathan MD | Dyne Therapeutics | 39 | |
| Gerhard Frey | Bioatla | N/A | |
| Amy Reilly | Dyne Therapeutics | 50 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Farrell PharmD | Trevi Therapeutics | N/A | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Eric LLM | Inventiva Sa | 50 | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Alice PharmD | Inventiva Sa | 53 | |
| Kristina Meyer | Inventiva Sa | N/A | |
| Danine Summers | Trevi Therapeutics | 66 | |
| John MBA | Dyne Therapeutics | 61 | |
| David MD | Mineralys Therapeutics, Common | 69 | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Katie McManus | Trevi Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.59 |
GlycoMimetics Leadership Team
Elected by the shareholders, the GlycoMimetics' board of directors comprises two types of representatives: GlycoMimetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlycoMimetics. The board's role is to monitor GlycoMimetics' management team and ensure that shareholders' interests are well served. GlycoMimetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlycoMimetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rachel King, President CEO, Founder, Director | ||
| Edwin MD, Senior Officer | ||
| Brian Hahn, CFO and Principal Accounting Officer | ||
| Armand Girard, Senior Vice President Strategy and Corporate Development | ||
| Harout Semerjian, President CEO | ||
| Chinmaya Rath, Senior Officer | ||
| John Magnani, Chief Scientific Officer, VP and Director | ||
| Stephanie CPA, Vice Accounting | ||
| Bruce Johnson, Senior Officer | ||
| Shantha Tyavanagimatt, Senior Operations | ||
| Christian DinneenLong, General Secretary |
GlycoMimetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlycoMimetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 7.15 M | ||||
| Shares Outstanding | 64.48 M | ||||
| Shares Owned By Insiders | 3.12 % | ||||
| Shares Owned By Institutions | 47.91 % | ||||
| Number Of Shares Shorted | 5.64 M | ||||
| Price To Earning | (7.99) X | ||||
| Price To Book | 1.87 X | ||||
| Price To Sales | 2,063 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether GlycoMimetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GlycoMimetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Glycomimetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Glycomimetics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Quarterly Revenue Growth (1.00) | Return On Assets (0.59) | Return On Equity (1.04) |
The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.